BerGenBio ASA Registered Shs Aktie [WKN DE: A2DPC0 / ISIN: NO0010650013]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu BerGenBio ASA Registered Shs

21.01.19		BerGenBio Announces Start of Phase I Trial Evaluating ADCT-601, a Novel Anti-AXL ADC, in Patients With Advanced Solid Tumours (PR Newswire)
21.01.19		BerGenBio Announces Start of Phase I Trial Evaluating ADCT-601, a Novel Anti-AXL ADC, in Patients With Advanced Solid Tumours (PR Newswire)
09.01.19		BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149 (PR Newswire)
09.01.19		BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149 (PR Newswire)
04.01.19		BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in High-risk MDS (PR Newswire)
04.01.19		BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in High-risk MDS (PR Newswire)
12.12.18		BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference (PR Newswire)
12.12.18		BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference (PR Newswire)
03.12.18		BerGenBio Reports 43% Response Rate With Bemcentinib Monotherapy in AXL Positive R/R AML/MDS Patients at ASH (PR Newswire)
03.12.18		BerGenBio Reports 43% Response Rate With Bemcentinib Monotherapy in AXL Positive R/R AML/MDS Patients at ASH (PR Newswire)
21.11.18		BerGenBio Appoints Cancer Drug Development Specialist Alan Barge MD as Interim Chief Medical Officer (PR Newswire)
21.11.18		BerGenBio Appoints Cancer Drug Development Specialist Alan Barge MD as Interim Chief Medical Officer (PR Newswire)
13.11.18		BerGenBio ASA: Results for the Third Quarter 2018 (PR Newswire)
13.11.18		BerGenBio ASA: Results for the Third Quarter 2018 (PR Newswire)
06.11.18		BerGenBio Reports ~80% Improvement in PFS of AXL-positive vs AXL-negative NSCLC Patients in Bemcentinib + KEYTRUDA PhII Combination Trial (PR Newswire)
06.11.18		BerGenBio Reports ~80% Improvement in PFS of AXL-positive vs AXL-negative NSCLC Patients in Bemcentinib + KEYTRUDA PhII Combination Trial (PR Newswire)
02.11.18		BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC (PR Newswire)
02.11.18		BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC (PR Newswire)
09.10.18		BerGenBio to Present Interim Phase II Clinical, Preclinical and Biomarker Data With Selective AXL Inhibitor Bemcentinib at ESMO (PR Newswire)
09.10.18		BerGenBio to Present Interim Phase II Clinical, Preclinical and Biomarker Data With Selective AXL Inhibitor Bemcentinib at ESMO (PR Newswire)
05.10.18		BerGenBio Enters Second Stage of Phase II Trial With Selective AXL Inhibitor bemcentinib in Combination With KEYTRUDA® in Patients With Advanced NSCLC (PR Newswire)
05.10.18		BerGenBio Enters Second Stage of Phase II Trial With Selective AXL Inhibitor bemcentinib in Combination With KEYTRUDA® in Patients With Advanced NSCLC (PR Newswire)
25.09.18		BerGenBio: Updated PhII Clinical Data With Selective AXL Inhibitor Bemcentinib Strengthens its Potential to Improve NSCLC Patient Outcomes (PR Newswire)
25.09.18		BerGenBio: Updated PhII Clinical Data With Selective AXL Inhibitor Bemcentinib Strengthens its Potential to Improve NSCLC Patient Outcomes (PR Newswire)
05.09.18		BerGenBio to Present Interim Phase 2 Clinical Data With Selective AXL Inhibitor Bemcentinib in Non-small Cell Lung Cancer at WCLC (PR Newswire)
05.09.18		BerGenBio to Present Interim Phase 2 Clinical Data With Selective AXL Inhibitor Bemcentinib in Non-small Cell Lung Cancer at WCLC (PR Newswire)
30.08.18		BerGenBio to Present at the 20th Annual Global Investment Conference in New York City September 4-6, 2018 (PR Newswire)
30.08.18		BerGenBio to Present at the 20th Annual Global Investment Conference in New York City September 4-6, 2018 (PR Newswire)
21.08.18		BerGenBio ASA: Results for the Second Quarter and First Half 2018 (PR Newswire)
21.08.18		BerGenBio ASA: Results for the Second Quarter and First Half 2018 (PR Newswire)
26.06.18		Selective AXL Inhibitor Bemcentinib Meets Pre-specified Efficacy Endpoint in Stage 1 of NSCLC Phase II Combination Trial With KEYTRUDA® (PR Newswire)
26.06.18		Selective AXL Inhibitor Bemcentinib Meets Pre-specified Efficacy Endpoint in Stage 1 of NSCLC Phase II Combination Trial With KEYTRUDA® (PR Newswire)
03.06.18		BerGenBio Provides Interim Update on Phase II Clinical Programme With Selective Oral AXL Inhibitor Bemcentinib (PR Newswire)
29.05.18		BerGenBio - Invitation to Conference Call: Interim Update on Ph II Clinical Programme With Selective AXL Inhibitor Bemcentinib Being Presented at ASCO (PR Newswire)
29.05.18		BerGenBio - Invitation to Conference Call: Interim Update on Ph II Clinical Programme With Selective AXL Inhibitor Bemcentinib Being Presented at ASCO (PR Newswire)
18.05.18		BerGenBio to Present Interim Clinical and Biomarker Data With Selective AXL Inhibitor Bemcentinib in AML and MDS at EHA (PR Newswire)
15.05.18		BerGenBio ASA: Results for the First Quarter 2018 (PR Newswire)
15.05.18		BerGenBio ASA: Results for the First Quarter 2018 (PR Newswire)
14.05.18		BerGenBio Participation at Upcoming Healthcare Investor and Life Sciences Industry Conferences (PR Newswire)
14.05.18		BerGenBio Participation at Upcoming Healthcare Investor and Life Sciences Industry Conferences (PR Newswire)
18.04.18		BerGenBio: Promising Data Highlighting Selective AXL Inhibitor Bemcentinib's Potential to Improve Efficacy of Checkpoint Inhibitors Presented at AACR (PR Newswire)
18.04.18		BerGenBio: Promising Data Highlighting Selective AXL Inhibitor Bemcentinib's Potential to Improve Efficacy of Checkpoint Inhibitors Presented at AACR (PR Newswire)
13.04.18		Promising Pre-clinical Data Supporting BerGenBio's Pipeline to be Published and Presented at Upcoming Leading Conferences (PR Newswire)
13.04.18		Promising Pre-clinical Data Supporting BerGenBio's Pipeline to be Published and Presented at Upcoming Leading Conferences (PR Newswire)
13.04.18		BerGenBio ASA Announces Successful NOK 187.5 Million (USD 24 Million) Private Placement of New Shares (PR Newswire)
10.04.18		BerGenBio Completes Recruitment Into First Stage of Phase II NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA® (PR Newswire)
10.04.18		BerGenBio Completes Recruitment Into First Stage of Phase II NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA® (PR Newswire)
22.03.18		BerGenBio to Present Overview of Phase II Clinical Trial Portfolio Combining Bemcentinib With KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe (PR Newswire)
22.03.18		BerGenBio to Present Overview of Phase II Clinical Trial Portfolio Combining Bemcentinib With KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe (PR Newswire)
15.03.18		BerGenBio: Promising Data Highlighting Bemcentinib's Potential to Improve Efficacy of Checkpoint Inhibitors to be Presented at AACR Annual Meeting (PR Newswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Elon Musk prognostiziert Kursrückgang bei Bitcoin

Solana Kurs Prognose: 1.000 US-Dollar in 2025?

Palantir-Aktie nach Gewinn- und Umsatzplus deutlich höher

100.000-Dollar-Schwelle unterschritten: Bitcoin gibt nach

DeepSeek sorgt für Turbulenzen an den Krypto-Märkten - Crash oder Kaufgelegenheit?

Bitcoin, Ether und Co. im Check - ChatGPTs Top-Kryptowährung für 2025

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	04.02.2025 11:51
Kaufwert:	EUR
	Hinzufügen Speichern